U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
April 30, 2024 04:00 ET
|
Alvotech
Alvotech will manufacture its high-concentration interchangeable biosimilar to Humira® (adalimumab) for Quallent Pharmaceuticals The strategic agreement is in alignment with Alvotech’s U.S....
Alvotech semur við Quallent Pharmaceuticals um markaðssetningu á hliðstæðu við Humira í Bandaríkjunum
April 30, 2024 04:00 ET
|
Alvotech
Alvotech mun framleiða líftæknilyfjahliðstæðu sína í háum styrk með útskiptileika við Humira (adalimumab) fyrir Quallent Pharmaceuticals, dótturfélag Cigna Alvotech (NASDAQ: ALVO) tilkynnti í dag...
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
April 30, 2024 04:00 ET
|
Alvotech
Alvotech will manufacture its high-concentration interchangeable biosimilar to Humira® (adalimumab) for Quallent Pharmaceuticals The strategic agreement is in alignment with Alvotech’s U.S....
WISeKey International Holding Ltd Receives Extension of the Deadline for the Publication of its FY 2023 Annual Report and Releases Unaudited FY 2023 Key Metrics
April 30, 2024 01:00 ET
|
Wisekey International Holding Ltd.
Zug, Switzerland, April 30, 2024 (GLOBE NEWSWIRE) -- Also Files Form 12b-25 with SEC Related to Annual Report on Form 20-F Ad hoc announcement pursuant to Art. 53 of SIX Listing Rules – WISeKey...
Jiayin Group Inc. Filed Annual Report on Form 20-F for Fiscal Year 2023
April 29, 2024 22:30 ET
|
Jiayin Group Inc.
SHANGHAI, China, April 29, 2024 (GLOBE NEWSWIRE) -- Jiayin Group Inc. (“Jiayin” or the “Company”) (NASDAQ: JFIN), a leading fintech platform in China, today announced that it has filed its annual...
Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024
April 29, 2024 21:05 ET
|
Mesoblast Limited
NEW YORK, April 29, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for...
Foremost Lithium Announces Closing of the Second Tranche of its Flow-Through Private Placement for Gross Proceeds of $1.455M
April 29, 2024 21:00 ET
|
Foremost Lithium Resource & Technology Ltd.
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, April 29, 2024 (GLOBE NEWSWIRE) -- Foremost Lithium Resource &...
Mustang Bio Announces Pricing of $4 Million Public Offering
April 29, 2024 20:00 ET
|
Mustang Bio, Inc.
WORCESTER, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical...
TFF Pharmaceuticals Announces Pricing of $4.8 Million Public Offering
April 29, 2024 20:00 ET
|
TFF Pharmaceuticals, Inc.
FORT WORTH, Texas, April 29, 2024 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc (Nasdaq: TFFP) (the “Company” or “TFF Pharmaceuticals”), a clinical-stage biopharmaceutical company focused on...
Sound Financial Bancorp, Inc. Q1 2024 Results
April 29, 2024 19:34 ET
|
Sound Financial Bancorp, Inc.
SEATTLE, April 29, 2024 (GLOBE NEWSWIRE) -- Sound Financial Bancorp, Inc. (the "Company") (Nasdaq: SFBC), the holding company for Sound Community Bank (the "Bank"), today reported net income of $770...